Verification before purchase is a sequence, not a checklist. Request five documents, read four numbers, decide what a blank field means, and then apply the one check that matters for your specific compound. That last step is where most buyers stop too early.
The generic advice — "look for third-party testing" — is correct and almost useless on its own, because the decisive test differs by molecule. Independent results sit in the lab test database, and the reason a purity percentage should not lead this process is set out in peptide purity standards.
What should you ask a peptide vendor for before you pay?
Ask for five things, and ask for them together rather than one at a time. A batch-matched certificate of analysis from a named third-party laboratory, a mass spectrum for that batch, a quantitative net content or fill figure, the stated salt form, and an LAL endotoxin result if the product is injectable. Four of those five are cheap for an honest vendor to supply and awkward for a dishonest one. A purity percentage alone answers the easiest question in the set and cannot answer the others.
Send the request as a single message, before payment, in this order:
"Can you send the certificate of analysis for the exact batch I would receive?" Batch-matched is the whole request. A certificate for a different lot describes a different vial.
"Does it include a mass spectrum, and what mass did it report?" This is the identity question. Purity does not answer it.
"What is the net peptide content or assayed fill for that batch?" This is the quantity question, and it is the one that fails most often.
"Which salt form is it, and is the label milligram figure peptide mass or total mass?" This decides how much peptide you actually bought.
"Is there an LAL endotoxin result on that lot?" On an injectable, this is not optional.
A vendor who answers all five in one reply, with a document rather than a sentence, has told you more about its operation than any trust badge on its homepage. A vendor who answers three and goes quiet on the other two has also told you something.
How do you tell third-party testing from a vendor's own document?
Third-party testing means a laboratory with no financial interest in the result generated the number, and the certificate should make that checkable rather than assertable. The tell is specificity: a named laboratory, a report date, a batch or lot identifier that matches the vial, a stated method and column, and a sample-received date preceding the report date. A vendor's in-house document typically carries the vendor's own branding, no laboratory name, no method section, and a batch field that is either blank or generic.
Independent laboratory report | Vendor-supplied document | |
|---|---|---|
Who ran the assay | A named laboratory with no stake in the result | The seller, or an unnamed party |
Batch identifier | Specific lot, matching the vial you receive | Blank, generic, or a different lot |
Method stated | Column, mobile phase, wavelength, instrument | Usually absent |
Dates | Sample received and report issued, both present | One date or none |
Failure visibility | The laboratory reports what it measured | Only passing results are ever shown |
What it establishes | The tested batch met the stated specification | That the seller says it did |
Selection bias | Present — vendors choose which reports to publish | Total |
Both document types share one limitation worth stating: even a genuine independent report is a certificate the vendor chose to show you. It describes a batch that passed. Which laboratory ran it, and what a named laboratory does and does not guarantee, is the subject of third-party peptide testing labs.
How do you read the four numbers that come back?
Read them in the order identity, quantity, contamination, purity — which is roughly the reverse of the order they appear on most certificates. Mass first, because a purity figure on the wrong molecule is worthless. Fill second, because that is where this market actually fails. Endotoxin third, because it is the one axis with a documented Class I recall behind it. Purity last, against the platform composite of 99.50 across 10,110 recency-weighted tests (verified August 2026), and only to see whether it is anomalously low.
Number | What good looks like | What to do with it |
|---|---|---|
Mass | Matches the reference mass for the compound, on a batch-matched spectrum | If it is absent, you have no identity evidence at all |
Fill or net content | Assayed milligrams within a few percent of label | If absent, assume the label and check the compound's recorded variance |
Endotoxin | A stated EU/mL figure on the batch, not a generic "passes" | Blank on an injectable is a stop, not a shrug |
Purity | Anywhere near the 99.50 composite | Only informative when unusually low, as with a 50.63% outlier |
The Purity Index gives the per-compound benchmark to read a purity figure against, and line-by-line interpretation of a report already in hand is covered in how to read peptide lab test results.
What should you do when a field on the certificate is blank?
Treat a blank field as an unanswered question rather than a passed test, and decide by which question it is. A missing salt form is recoverable with one email. A missing endotoxin result on an injectable is not recoverable at all, because no downstream check can substitute for it and this market has produced a Class I recall on exactly that axis. The practical distinction is whether the missing information can be supplied later or whether its absence means the batch was never tested for it.
Blank field | What it usually means | What to do |
|---|---|---|
Endotoxin, on an injectable | The batch was never LAL-tested | Do not proceed. A Class I recall of a GenoGenix NAD+ injection was classified on 21 October 2025 for endotoxin contamination |
Mass spectrum | Only HPLC was run | Request it. Without a mass there is no identity evidence, only homogeneity |
Net content or fill | Quantity was never assayed | Ask. If refused, price the compound as if the label were unreliable |
Salt form | Nobody thought to state it | Ask. It changes how many milligrams of peptide you bought |
Batch or lot number | The document is generic | Treat the certificate as marketing. It cannot be tied to your vial |
Laboratory name | In-house testing, or none | Not third-party. Weight it accordingly |
Report date | Old or fabricated document | Ask for the issue date and compare with the batch date |
Documents that are evasive rather than merely incomplete — mismatched batch numbers, recycled chromatograms, database traps — are covered in red flags in peptide certificates of analysis, and the pyrogen question in endotoxin testing and the LAL assay.
Why does the right check depend on the compound?
Because each molecule has a characteristic way of being wrong, and a single checklist applied to every vial checks the wrong thing most of the time. Tirzepatide's identity is effectively solved at 99.75% across 930 independent tests while its fill runs +2.6% to +26.7% over label. GHK-Cu's failure mode is a missing metal that no purity test detects. PT-141 can be substituted by a compound one dalton away. FOXO4-DRI has a defining property no laboratory in this market can measure. Thymalin cannot be identity-tested at all.
Compound | The check that matters | Why | What a purity figure adds |
|---|---|---|---|
Tirzepatide and the GLP-1 class | Assayed fill quantity | Variance +2.6% to +26.7%, on a schedule titrated in 2.5 mg steps | Almost nothing — identity is solved at 99.75% |
Elemental copper content | Copper is roughly 18% of the molecule and HPLC detects no metals | Nothing — copper-free GHK returns a clean result | |
High-resolution mass or MS/MS | Melanotan II sits about 1.0 Da away on 1,025 and co-elutes | Nothing — a substituted vial reads identically | |
Chiral analysis — unavailable | The all-D configuration is invisible to every assay sold here | Nothing — an L-built vial passes every test | |
LAL endotoxin and sterility | An undefined extract has no reference sequence and no target mass | Nothing — a percentage against no declared analyte | |
Semaglutide | Stated salt form | FDA treats semaglutide sodium and acetate as different active ingredients | Nothing about what was weighed |
PEG-MGF | Dispersity of the PEG chain | PEG is polydisperse in 44 Da steps | A single clean peak arguably signals the PEG is absent |
SS-31 | Mass, for one substitution only | Dmt→Tyr is a clean −28 Da; the D-Arg substitution is undetectable | Partial coverage at best |
Which check matters most on tirzepatide and the GLP-1 class?
The assayed fill quantity, by a wide margin. Tirzepatide records 99.75% average purity across 930 independent tests from Freedom Diagnostics, Kovera, ILS, Accumark and MZ Biolabs across 227 shops selling (verified August 2026) — one of the deepest datasets on this platform — while quantity variance runs +2.6% to +26.7%, with vials labelled 10 to 65 mg testing between 10.71 and 68.1 mg. Identity is not the failure mode here. Quantity is.
The arithmetic is what makes it decision-relevant rather than merely untidy. A 26.7% overage is larger than the 2.5 mg increment the entire titration schedule is built from, so a buyer stepping up one rung by label may have moved two by content. On an intended amount below the starting rung, the same proportional error is larger than the amount being aimed at. Retatrutide shows the same pattern with a tighter band: 99.67% across 1,150 tests, individual results 99.52% to 99.98%, and fill variance −4% to +22.5% on a compound titrated in 1-2 mg steps. Ask for the assayed fill in milligrams for the specific lot, and if it is not available, treat the label as an estimate. The mechanics of why a label milligram is not a peptide milligram are in why 10 mg isn't 10 mg.
Which check matters most on GHK-Cu?
Whether the copper is present, which is a question no certificate in this market answers. GHK-Cu is a 1:1 copper complex of glycyl-histidyl-lysine, and the metal accounts for roughly 18% of the molecule — a mass gap of about 62.5 Da between the 340.38 Da free tripeptide and the ~403 Da complex. HPLC separates by hydrophobicity and detects no metals whatsoever, so a vial of pure copper-free GHK returns an excellent purity figure. GHK-Cu's 99.66% across 736 independent HPLC tests contains no information about copper at all.
Two things make this harder than it looks. PubChem files the copper-free 340.38 Da peptide under the synonyms "GHK-Cu", "Copper Peptide" and "Prezatide", so the conflation is baked into the reference layer a buyer would check against. And elemental analysis, the assay that would measure copper directly at 1:1 stoichiometry, is not offered by any vendor or laboratory serving this market. The practical substitute is a batch-matched mass spectrum: roughly 403 daltons is the copper complex, 340.38 is the copper-free tripeptide wearing its name. Ask for the mass, read the number, and do not accept a purity percentage as an answer. The full case is in heavy metals testing.
Which check matters most on PT-141?
A high-resolution mass spectrum or MS/MS fragmentation on the batch, and nothing cheaper will do. Bremelanotide sits at 1,025.2 g/mol and melanotan II at 1,024.18 — a difference of about 1.0 Da on 1,025, under 0.1%. The two peptides share a backbone, share the Asp5→Lys10 lactam bridge, co-elute on reversed-phase columns, and cannot be reliably separated by nominal-mass mass spectrometry. PT-141's 99.70% across 242 independent HPLC tests would read identically if the vial contained melanotan II.
The asymmetry is what makes this worth checking rather than merely knowing. The substitution risk runs one way: someone ordering bremelanotide, an FDA-approved drug under NDA 210557, can receive melanotan II, a substance approved in no country. Nobody is substituting in the other direction. Ask for high-resolution MS or MS/MS on the specific lot, and if the vendor cannot supply it, understand that the identity question stays open regardless of how good the purity number looks. Mass resolution and its limits are covered in mass spectrometry for peptides.
Which check can nobody run on FOXO4-DRI?
The chirality check, which is the only one that would matter — and it is unavailable at any price in this market. FOXO4-DRI's entire design is its all-D-amino-acid configuration, and D and L residues share identical molecular formulas, identical molecular weights and identical monoisotopic masses. They co-elute on the achiral reversed-phase columns used for purity testing and produce identical mass spectra. A vial synthesised from ordinary L-amino acids reports ~5,358 Da, shows a single clean peak, matches every specification on the certificate, and is degraded by serum proteases within minutes.
That is the uncomfortable case at the centre of this article: no red flag, no anomaly, a perfect certificate and a wrong product. The Purity Index records FOXO4-DRI at 99.55 across 47 recency-weighted tests from 11 laboratories (verified August 2026), and none of those 47 tests addresses the question. Detection needs chiral chromatography or enantioselective analysis, which we have not seen offered by any vendor or third-party laboratory serving this market. The synthesis difficulty compounds it: at 46 residues all-D, this is a long solid-phase synthesis with accumulating deletion and truncation risk at every coupling step. FOXO4-DRI price data shows a median of $16.00/mg (verified August 2026), roughly four times the platform-wide typical range of $3-5/mg, for a molecule whose defining property cannot be confirmed.
Why does thymalin need an endotoxin result rather than an identity result?
Because identity verification is not merely difficult on thymalin — it does not apply. Thymalin is an undefined calf thymus extract with no reference sequence, no target mass and no authenticated standard, which means there is nothing for a laboratory to hold a batch against. Mass spectrometry produces a spectrum of many masses with no target to compare them to. A "99% purity" figure on a thymalin certificate measures peak area against no declared analyte, which is a category error rather than a quality signal.
What remains checkable is everything that does not depend on knowing what the molecule is: sterility, pyrogens, and the physical state of the vial. A vial labelled thymalin could contain a genuine bovine thymus fraction or a different animal-tissue extract, and no certificate in circulation would distinguish them — so the questions worth asking are whether it is sterile and whether it is pyrogen-free. Contrast this with SS-31 or FOXO4-DRI, where one specific attribute escapes routine testing; here the entire concept of identity verification is unavailable. Sterility, container closure and vial dating are covered in sterility testing and USP 71.
How should price and shop reputation feed the decision?
Price is the one signal that varies when purity does not, so a wide per-milligram spread inside a narrow purity band is carrying information the certificate is not. PT-141 price data shows 65 shops in stock at a median of $4.40 per milligram, lowest $2.00/mg on a 10 mg vial and highest $9.59/mg on a 5 mg vial (verified 10 August 2026) — a near-fivefold spread across products all clearing 99% purity. What differs is most plausibly fill quantity, testing burden and endotoxin control.
Two rules make price usable rather than merely interesting. Compare within a single vial size, because fixed per-vial costs push the per-milligram figure up on small vials and down on large ones, making cross-size comparisons meaningless. And read an unusually low per-milligram offer as a question rather than a bargain: the cheapest way to hit a price point on a compound whose purity is already at market is to put less in the vial. Vendor-level history sits in community-verified shop reviews, where trust scores weight community reviews and independently verified purity equally at 50% each.
What can none of these checks establish?
A complete pre-purchase verification confirms what was in a tested batch on a tested date, and stops there. It does not confirm the contents of the specific vial that ships to you, the storage and cold-chain history between the test and your door, whether the compound does anything in humans, or whether any dose in circulation has ever been validated. Those are separate questions, and treating a good certificate as an answer to them is the most common error made by buyers who do everything else right.
What the procedure cannot establish | Why | Where the answer lives instead |
|---|---|---|
The contents of your vial | A certificate describes a tested batch, not every unit in it | Nowhere — this is an irreducible limit |
Storage history since testing | Degradation happens after the assay | Cold chain and appearance on arrival |
Chirality | No laboratory in this market offers chiral analysis | Unanswerable at present |
Metal content | No laboratory in this market offers elemental analysis | Unanswerable at present |
Whether the compound works | Analytical testing is not clinical evidence | The compound's science article |
Whether the dose is validated | A certificate says nothing about dosing | The compound's dosing article, and a clinician |
Upstream manufacturing controls | A batch result is not a quality system |
Which pre-purchase verification claims survive scrutiny?
Claims about what a document proves mostly fail; claims about what a specific assay measures mostly hold. The pattern across this record is that verification advice fails when it generalises — one threshold, one checklist, one reassurance applied to every compound — and holds when it is specific about which assay answers which question on which molecule. Of the eight claims below, three survive intact, one survives only with a qualification, and four are false against this record.
Claim | What this record shows | Verdict |
|---|---|---|
"Third-party tested means verified" | Establishes the tested batch met a specification; says nothing about your vial or the untested axes | Partly true, over-read |
"A high purity number means it is legit" | PT-141 and melanotan II differ by ~1.0 Da and co-elute | False |
"One checklist works for every peptide" | The decisive check differs on all eight compounds tabled above | False |
"You can verify anything if you pay enough" | Chiral and elemental analysis are not offered by anyone serving this market | False |
"A blank endotoxin field is a formality" | Class I recall classified 21 October 2025 for endotoxin in an injectable | False |
"Batch-matching the CoA matters" | A certificate for another lot describes another vial | True |
"Fill quantity is worth asking about" | Recorded variance −57.6% to +94% | True |
"Price spread inside one purity band is informative" | PT-141 spans $2.00 to $9.59/mg at uniform purity | True |
What does Peptigrity's data add before you buy?
It supplies the benchmark a single certificate cannot: what this compound normally scores, who normally tests it, and what it normally costs. Peptigrity tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026), weighting community reviews and independently verified HPLC purity equally at 50% each in every trust score. A vendor's 99.4% means one thing on a compound whose composite is 99.75 and something else on one whose composite is 98.51.
Taking the deepest dataset as the worked case: tirzepatide records 99.75% average purity across 930 independent tests from five named laboratories across 227 shops selling (verified August 2026), and tirzepatide price data shows 14 shops in stock, median $5.67/mg, lowest $1.17/mg on a 60 mg vial (verified 9 August 2026) across 48 compared offers. Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing.
The limits are worth stating as plainly as the strengths. These are certificates vendors chose to publish, so the composite is an upper bound on market quality rather than an estimate of it. Composites built on small test counts move on single results. And no aggregate figure, however large, tells you what is in the vial in front of you — it tells you what to expect and therefore what an anomaly looks like.
The trial that would settle whether pre-purchase verification works
Nobody has tested whether this procedure improves outcomes, and the study is straightforward to specify. The claim implicit in every buyer guide, including this one, is that requesting more documents produces better vials. That is an empirical claim and it has never been measured. Settling it needs blinded purchasing at scale across the 97.38 to 99.75 purity range this market spans, an independent panel run on every vial received, and a willingness to publish named failures.
Element | What it would need to be |
|---|---|
Design | Prospective, blinded purchase study across vendors, randomised to a full document request or a purchase with no request |
Population | 300 orders across 15 compounds spanning the failure modes tabled above |
Intervention | The five-item request in one arm; standard checkout in the other |
Primary endpoint | Rate of vials failing an independent post-hoc panel on identity, fill, salt form and endotoxin |
Secondary endpoints | Whether document quality predicts fill accuracy; whether price per milligram predicts failure; vendor response rate to each of the five requests |
Why it has not been run | It requires buying from vendors at scale and publishing named failures, and no funded body audits a market it does not sell into |
What a null result would mean | That paperwork sorts vendors by willingness to answer rather than by product quality — worth knowing either way |
The order of operations
Run the checks in the order that eliminates the most possibilities per question, and stop when a hard fail appears. Identity before quantity, quantity before contamination, contamination before purity, and the compound-specific check inserted at whichever position it belongs for that molecule. On tirzepatide it belongs at step two; on GHK-Cu it replaces step one; on FOXO4-DRI it cannot be run and the honest response is to price that uncertainty rather than assume it away.
Check | What it confirms | How | Red flag |
|---|---|---|---|
1. Batch-matched certificate | The document describes your lot | Lot number on the report matches the vial | Generic or missing batch field |
2. Named third-party laboratory | Someone without a stake measured it | Laboratory named, method and dates stated | Vendor's own document presented as independent |
3. Mass spectrum | The molecule is the labelled one | MS or MS/MS on the batch, read against the reference mass | Purity offered in place of a mass |
4. Compound-specific check | The characteristic failure mode for that molecule | Varies: fill, metal, high-resolution mass, chirality, endotoxin | Vendor treats every compound as identical |
5. Net content or assayed fill | Milligrams of peptide, not of powder | Amino acid analysis or quantitative assay | Blank, on a market with −57.6% to +94% on record |
6. Salt form | What was actually weighed | Stated on the certificate | Not stated |
7. LAL endotoxin | No pyrogens, on an injectable | Batch LAL figure in EU/mL | Blank field, after a Class I recall |
8. Purity, last | Homogeneity of detected species | RP-HPLC against the compound's own composite | Anomalously low, or promised at "above 98%" |
Frequently Asked Questions
What should I ask a peptide vendor before buying?
Ask for five things in one message: a batch-matched certificate of analysis from a named third-party laboratory, a mass spectrum for that batch, a quantitative net content or assayed fill figure, the stated salt form, and an LAL endotoxin result if the product is injectable. How the vendor handles the two awkward requests — fill and endotoxin — is more informative than the documents themselves.
Can you verify a peptide is real before it arrives?
Only through the paperwork, and only for the batch that was tested. A batch-matched mass spectrum is the strongest pre-purchase evidence of identity available, because it reports the molecule rather than its homogeneity. It still describes a tested batch rather than the specific vial that ships, which is an irreducible limit of the process rather than a solvable problem.
Is a certificate of analysis enough to trust a peptide vendor?
No. A certificate describes one batch on one date, and it is a document the vendor chose to show you. It cannot establish storage history, the contents of your individual vial, or anything about efficacy or dose validity. It is necessary and not sufficient, which is why fill quantity, salt form and endotoxin are asked for separately.
Which peptide quality check matters most?
It depends entirely on the compound. Tirzepatide needs an assayed fill figure because variance runs +2.6% to +26.7% while purity sits at 99.75%. GHK-Cu needs metal content, PT-141 needs high-resolution mass, thymalin needs endotoxin because identity testing cannot apply, and FOXO4-DRI needs a chirality answer no laboratory in this market can supply.
What does it mean if the endotoxin field is blank?
It usually means the batch was never tested for pyrogens. On an injectable that is a stop rather than a question, because filtration removes bacteria without removing what bacteria leave behind, and FDA classified a Class I recall of a GenoGenix NAD+ injection for endotoxin contamination on 21 October 2025.
Are there peptide quality checks nobody can run?
Two, and both matter. Chiral analysis, which would distinguish an all-D peptide such as FOXO4-DRI from a cheap L-built copy, and elemental analysis, which would confirm the copper in GHK-Cu. Neither is offered by any vendor or third-party laboratory serving this market, so on those compounds the decisive question stays open.
Browse the weight loss and metabolic peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For per-injection volume, use the tirzepatide calculator alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.
This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
